Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 4Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 7

Study Type

Interventional 7

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 416Lymphoma 406Lymphoma, Non-Hodgkin 344Leukemia, Lymphocytic, Chronic, B-Cell 313Lymphoma, Follicular 301Lymphoma, Mantle-Cell 226Lymphoma, B-Cell, Marginal Zone 161Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 85Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Hematologic Neoplasms 22Dendritic Cell Sarcoma, Interdigitating 22Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Hematologic Diseases 13Lymphoproliferative Disorders 12

Interventions

rozanolixizumab 11efgartigimod alfa 10zilucoplan 8Prednisone 8Cyclophosphamide 8ravulizumab 7Rituximab 7Pyridostigmine Bromide 7telitacicept 6fludarabine 6Tacrolimus 6Mycophenolic Acid 6eculizumab 5Immunoglobulins, Intravenous 5Hizentra 4Azathioprine 4Steroids 3HBM9161 3Data Collection 3Amifampridine 3thymoglobulin 2inebilizumab 2Thymectomy 2Prednisolone 2Methylprednisolone 2Methotrexate 2Exercise 2Diagnostic Self Evaluation 2Blood Specimen Collection 2tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Myasthenia Gravis × Rituximab × Clear all
NCT05868837 2025-08-01

REFINE

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 3 Recruiting
40 enrolled

Myasthenia Gravis

NCT07071246 2025-07-17

Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis

Tang-Du Hospital

Phase NA Active not recruiting
30 enrolled

Myasthenia Gravis

NCT02950155 2024-10-26

Rinomax

Karolinska Institutet

Phase 3 Completed
47 enrolled 24 charts

Myasthenia Gravis

NCT05332587 2022-05-02

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis

First Affiliated Hospital, Sun Yat-Sen University

Phase 3 Unknown
50 enrolled

Myasthenia Gravis

NCT02110706 2020-03-06

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

Yale University

Phase 2 Completed
52 enrolled 18 charts

Myasthenia Gravis

NCT00619671 2013-01-16

A Pilot Trial of Rituxan in Refractory Myasthenia Gravis

University of Vermont

Phase 1/2 Completed
10 enrolled

Myasthenia Gravis

NCT00774462 2012-12-11

FORCE

Assistance Publique - Hôpitaux de Paris

Phase 2 Completed
30 enrolled

Myasthenia Gravis, Myositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡